Interstitial Lung Disease in Systemic Lupus Erythematosus (SLE-ILD)

MD Examination Answer - 15 Marks

1. INTRODUCTION AND OVERVIEW

2. EPIDEMIOLOGY AND PREVALENCE

• SLE prevalence: 12-50 per 100,000; incidence 1.8-7.6 per 100,000/year
• Female predominance: 6- to 10-fold excess; disease is 3x more common in Blacks than Whites
• ILD in SLE: Affects only 1-15% of patients (clinically significant ILD is uncommon)
• Diffuse lung disease on biopsy or autopsy: reported in 4%, 33%, or 70% depending on histological criteria used - wide variation reflects differences in diagnostic thresholds
• Only 3% of SLE patients have clinical evidence of diffuse lung disease at onset; a disease resembling interstitial pulmonary fibrosis develops during follow-up in less than 5%
• 5-year survival exceeds 90%, but mortality is 3x higher than the general population

Risk Factors for ILD/Pulmonary Fibrosis in SLE:

• Increasing age
• History of pneumonitis (acute lupus pneumonitis)
• Presence of anti-RNP antibodies
• Patients older than 50 years
• Long-standing SLE
• Scleroderma-like features

3. FULL SPECTRUM OF PULMONARY MANIFESTATIONS IN SLE

4. PATHOGENESIS OF SLE-ILD

1. Immune complex deposition - Type III hypersensitivity; circulating immune complexes (anti-dsDNA + complement) deposit in pulmonary vasculature and alveolar walls
2. T-cell and B-cell dysregulation - Loss of self-tolerance drives autoantibody production (ANA, anti-dsDNA, anti-Sm, anti-RNP, anti-Ro/SSA, anti-La/SSB)
3. Complement activation - C3, C4 consumption; complement-mediated injury to alveolar epithelium and capillary endothelium
4. Cytokine-mediated fibrosis - TGF-β, IL-6, IL-1β drive progressive fibroblast activation and matrix deposition
5. Pulmonary capillaritis (for DAH subtype) - Neutrophil infiltration and fibrinoid necrosis of capillary walls; Fishman's describes this as "marked thickening of the interstitial compartment and infiltration by acute and chronic inflammatory cells with alveolar spaces filled with red blood cells and neutrophils"

5. HISTOPATHOLOGICAL PATTERNS

• Multicompartment involvement: airways, vasculature, and pleura
• Follicular bronchiolitis - enlarged peribronchiolar lymphoid follicles
• Lymphoplasmacytic inflammation
• Absence of subpleural honeycombing that characterizes UIP/IPF

6. CLINICAL FEATURES

A. Chronic ILD (Most Common Form)

• Insidious onset of exertional dyspnea and dry cough
• Predominantly basal crackles (Velcro crackles)
• Restrictive lung function defect or isolated reduction in DLCO
• Basal opacities on chest radiography
• Most commonly seen in: long-standing SLE; age >50 years; scleroderma-like features

• Pleuritic chest pain
• Functionally severe lung fibrosis
• Enlarged peribronchiolar lymphoid follicles on biopsy

B. Acute Lupus Pneumonitis (Severe Subtype)

• Seen in approximately 1-4% of SLE patients
• Life-threatening - mortality >50% once respiratory failure supervenes
• Can be the first presentation of SLE
• Clinically difficult to distinguish from severe infection and ARDS
• Symptoms: acute onset fever, cough, dyspnea, hemoptysis
• Histology: diffuse alveolar damage (DAD) - nonspecific
• Critical differential: infectious pneumonia (community-acquired or opportunistic given immunosuppression)

C. Shrinking Lung Syndrome

• Diaphragmatic dysfunction leading to progressive lung volume loss
• Elevated diaphragms bilaterally on imaging
• Restrictive physiology without true parenchymal ILD
• Mechanism: diaphragmatic myopathy or phrenic nerve neuropathy

D. Diffuse Alveolar Hemorrhage (DAH)

• Most characteristic of SLE among all CTDs
• Due to pulmonary capillaritis (immune complex mediated)
• Presents with hemoptysis, anemia, rapidly progressive dyspnea
• HRCT: diffuse bilateral ground-glass opacification
• BAL: progressively bloodier return in serial aliquots (diagnostic)
• Histology: pulmonary capillaritis with neutrophil infiltration of alveolar septa

7. INVESTIGATIONS

A. Pulmonary Function Tests (PFTs)

• Restrictive pattern: reduced TLC, FVC, FRC, RV
• Preserved FEV1/FVC ratio (>70%)
• Reduced DLCO - most sensitive early indicator; may be isolated reduction before restriction develops
• Hypoxemia at rest and on exercise; widened A-a gradient
• DLCO disproportionately reduced compared to lung volumes suggests pulmonary vascular involvement/PAH

B. Autoantibody Profile

• Mandatory screening in all ILD patients: ANA, anti-CCP, RF
• Specific to SLE: anti-dsDNA (most specific), anti-Sm, ANA (homogeneous pattern)
• Anti-RNP: risk factor for pulmonary fibrosis progression in SLE
• anti-Ro/SSA, anti-La/SSB: overlap with Sjogren syndrome
• Serology seroconversion noted in 51.2% of CTD-ILD patients on follow-up (Chinese cohort, n=1044) - repeat serologic testing recommended

C. Imaging

• Basal reticular opacities (most common)
• Mixed alveolar-interstitial pattern with coalescence in advanced disease
• Loss of lung volumes
• Pleural effusions common
• Honeycombing and pulmonary hypertension signs are late features

• Ground-glass opacification (GGO) - most common finding in active ILD
• Thickening of interlobular septa (reticular pattern)
• Centrilobular nodules
• Air-space consolidation (in OP or acute pneumonitis)
• Thin-walled perivascular cysts (in LIP pattern)
• Pleural effusion (most common overall HRCT finding in SLE)
• Pericardial effusion
• Pulmonary arterial hypertension signs (enlarged PA)

• Subpleural sparing (present in NSIP, absent in UIP)
• Absence of extensive honeycombing
• Esophageal dilation (SSc)
• Pleural and pericardial involvement
• Multicompartment disease

D. BAL (Bronchoalveolar Lavage)

• Lymphocytosis suggests NSIP/LIP pattern
• Progressive bloody return in serial aliquots = DAH
• Hemosiderin-laden macrophages on iron stain (Prussian blue positive) - confirms prior hemorrhage
• Must exclude infection before diagnosing inflammatory ILD

E. Surgical Lung Biopsy

• Usually NOT required in CTD-ILD because:
  • Histopathologic pattern has little impact on management in established CTD
  • Carries procedural risk in immunocompromised patients
• Consider when: diagnosis uncertain, unusual radiographic pattern, treatment unresponsive
• VATS biopsy preferred over open biopsy

F. Echocardiography

• Screen for PAH (common in SLE)
• RV dysfunction, elevated RVSP
• If RVSP >40 mmHg: right heart catheterization for definitive PAH diagnosis

8. DIAGNOSIS - MULTIDISCIPLINARY DISCUSSION (MDD)

"The gold standard for diagnosis of any interstitial lung disease includes multidisciplinary discussion including clinicians, radiologists, and pathologists with specific expertise in interstitial lung disease."

1. Clinical assessment (rheumatology + pulmonology)
2. HRCT pattern interpretation
3. Serological profile
4. BAL findings
5. Histopathology (if biopsy performed)

9. TREATMENT

A. General Principles

• Goal: Maximize lung function and minimize symptom burden
• Stability = successful outcome; improvement seen only in a subset
• Not all patients require treatment - decision based on: severity of ILD, rate of progression, age, comorbidities, CTD subtype, time since onset

B. Chronic Stable ILD

• Prednisolone 0.5-1 mg/kg/day initially
• Partial regression with corticosteroids seen in 9/14 SLE-ILD cases in one series - supports empirical trial
• OP pattern and methotrexate pneumonitis respond very well
• Use with caution if HRCT pattern resembles UIP/IPF - high-dose steroids are associated with major toxicity in IPF

• Mycophenolate mofetil (MMF) - preferred; well-tolerated
• Azathioprine - alternative
• Cyclophosphamide - for severe/progressive disease
• Hydroxychloroquine - baseline therapy for SLE, may have anti-fibrotic properties

C. Progressive ILD

• May slow progression of physiologic decline
• Uncertain role but used in refractory cases
• Also useful for DAH with pulmonary capillaritis

• Antifibrotic agent (tyrosine kinase inhibitor)
• Studied in CTD-ILD (IN-BUILD trial - primarily RA-ILD and other non-SSc CTD-ILD)
• ERS/EULAR 2026 guidelines: Insufficient evidence to recommend pirfenidone in CTD-ILD other than RA-ILD
• Role in SLE-ILD remains under investigation

• Shown to slow decline in lung function in RA-ILD
• May be considered in SLE-ILD as off-label option

• Associated with stabilization of lung function in some patients

D. Acute Lupus Pneumonitis

• IV methylprednisolone 1 g/day x 3 days (pulse)
• Followed by high-dose oral prednisolone
• Add IV cyclophosphamide if no rapid response
• Rituximab for refractory cases
• Aggressive management of infection (mandatory to rule out/treat simultaneously)
• ICU support for respiratory failure; mechanical ventilation if needed

E. Diffuse Alveolar Hemorrhage

• IV methylprednisolone (1 g/day x 3-5 days) - first-line
• IV cyclophosphamide - added for severe or recurrent cases
• Plasmapheresis - considered in cases with circulating immune complexes
• Rituximab - emerging evidence for refractory DAH

F. Monitoring and Follow-up

• Serial PFTs (FVC, DLCO) every 3-6 months
• HRCT: baseline, then as clinically indicated (not routinely repeated)
• Watch for: medication toxicity (osteoporosis, infections, metabolic effects from steroids; hepatotoxicity from azathioprine; hemorrhagic cystitis from cyclophosphamide)
• Pneumocystis jirovecii pneumonia (PCP) prophylaxis: cotrimoxazole when on high-dose steroids + immunosuppressants

10. ERS/EULAR 2026 GUIDELINES - KEY UPDATES

1. Screening: Evidence-based screening algorithms for ILD detection in each CTD, including SLE
2. For SLE specifically: The task force found insufficient evidence to support firm recommendations for screening and assessment of risk for ILD progression in SLE (low-certainty evidence)
3. GRADE methodology used - 25 PICO questions + 28 narrative questions addressed
4. Multidisciplinary approach strongly endorsed for diagnosis and management
5. Pirfenidone in CTD-ILD (non-RA): Insufficient evidence (specific PICO question)
6. Immunosuppression remains the cornerstone treatment
7. Antifibrotic agents: Emerging role, particularly nintedanib; use depends on ILD pattern (fibrotic NSIP/UIP-like pattern)
8. Individualized treatment based on CTD subtype, ILD pattern, and progression rate

11. PROGNOSIS

• SLE-ILD is generally milder and more slowly progressive compared to RA-ILD or SSc-ILD
• ILD in SLE is usually mild, with slow progression or stability over time
• Partial regression with corticosteroids is documented
• Acute lupus pneumonitis: mortality >50% once respiratory failure supervenes
• DAH carries high mortality if untreated
• Risk factors for poor prognosis: UIP pattern, high-resolution CT extent >30%, DLCO <40% predicted, PAH development
• SLE 5-year survival >90% overall, but 3x higher mortality than general population

12. SUMMARY TABLE FOR RAPID REVISION

REFERENCES (Primary Sources)

1. Murray & Nadel's Textbook of Respiratory Medicine - Chapter 92: Connective Tissue Diseases, pp. 2083-2097 (Sections: CTD-ILD approach, SLE-ILD, Diffuse Lung Disease, Acute Lupus Pneumonitis, Shrinking Lung Syndrome)
2. Fishman's Pulmonary Diseases and Disorders - Chapter 58: Pulmonary Manifestations of Collagen Vascular Disease, pp. 1024-1036 (Sections: Diffuse Alveolar Hemorrhage/Capillaritis in SLE, Histologic patterns)
3. Antoniou KM et al. ERS/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease. Ann Rheum Dis 2026; Eur Respir J 2026 [PMID: 40912974 / 40907995]
4. Bendstrup E et al. Systemic Lupus Erythematosus-related Lung Disease. Semin Respir Crit Care Med 2024;Jun [PMID: 38547915]
5. ATS/ERS/JRS/ALAT 2018 IIP Diagnosis Guidelines - Autoantibody testing recommendations in ILD

Examiner's Key Points to Score Full Marks:

• Distinguish ILD from other pulmonary manifestations of SLE (pleural, vascular, DAH, shrinking lung)
• Emphasize ILD is uncommon (1-15%) but clinically significant
• NSIP is the most common ILD pattern in SLE
• DAH is the most SLE-specific complication (pulmonary capillaritis mechanism)
• ATS guidelines mandate ANA, RF, anti-CCP in all ILD patients
• Multidisciplinary discussion is the diagnostic gold standard
• ERS/EULAR 2026 acknowledge insufficient evidence for firm screening/progression recommendations in SLE-ILD
• Treatment: steroids + MMF first-line; cyclophosphamide for severe; antifibrotics emergingYour credits are exhausted. Your daily credits reset tomorrow, or you can purchase a top-up for more.